Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03035929 · ClinicalTrials.gov registry record · Phase 1

Diagnosing Natriuretic Peptide Deficiency

A Phase 1 study, sponsored by Vanderbilt University Medical Center.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target

NCT03035929: Completed Phase 1 study, sponsored by Vanderbilt University Medical Center.

NCT03035929 is a Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03035929, a Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target

Study Summary

In this pilot study, the investigators will determine the response of the natriuretic peptide (NP) hormone system after a dose of intravenous dexamethasone (a steroid medication). The goal of the proposed project is to generate preliminary data that will be used to develop power calculations, inform cutoff ranges, and inform the timing of the NP response for larger subsequent studies. Aim: To determine the range of distribution and time course of natriuretic peptide (NP) responses to a single dose of dexamethasone IV 4 mg in healthy lean individuals. Hypothesis: Determination of the NP responses (the range and time course of changes in NP levels) to dexamethasone in 10 healthy individuals will inform the time course and frequency of blood sampling in a definitive prospective study, as well as enable investigators to perform a sample size calculation for a definitive prospective study.

Primary Outcome

Change in natriuretic peptide levels after drug administration

Interventions

  • DRUG Dexamethasone

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2017-01-01
Est. Completion 2018-01-01
Phase Phase 1

What the finished NCT03035929 record still lists

NCT03035929 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 1 intervention - of which Dexamethasone is the first listed.

NCT03035929 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03035929 about?

NCT03035929 is a clinical study titled "Diagnosing Natriuretic Peptide Deficiency". In this pilot study, the investigators will determine the response of the natriuretic peptide (NP) hormone system after a dose of intravenous dexamethasone (a steroid medication). The goal of the proposed project is to generate preliminary data that will be used to develop power calculations, inform...

What is the current status of trial NCT03035929?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-01-01. Estimated completion is 2018-01-01.

What interventions are being tested in trial NCT03035929?

The interventions under investigation include: Dexamethasone (DRUG).

Who is sponsoring clinical trial NCT03035929?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03035929's enrollment target sits among peer trials

10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03035929, the US trial registry maintained by the National Library of Medicine. NCT03035929 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.